Maria Baez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Baez has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Marino
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA
19 shared publications - Andrew Jones
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA
19 shared publications - Bernard Aloysius Fox
Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center
19 shared publications - Brian Piening
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, USA
19 shared publications - Carlo Bruno Bifulco
Providence Genomics, Portland, OR
19 shared publications - Carmen Ballesteros-Merino
Earle A. Chiles Research Institute (a division of Providence Cancer Institute), Portland, Oregon
19 shared publications
Latest Publications
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Expression profile of hCTLA-4 in humanized CTLA-4/FcγR mice bearing B16 or MCA-205 tumors
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Expression profile of hCTLA-4 in humanized CTLA-4/FcγR mice bearing B16 or MCA-205 tumors
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered murine anti-CCR8 antibodies
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered murine anti-CCR8 antibodies
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Expression profile of hCTLA-4 in humanized CTLA-4/FcγR mice bearing B16 or MCA-205 tumors
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Expression profile of hCTLA-4 in humanized CTLA-4/FcγR mice bearing B16 or MCA-205 tumors
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered human anti-CTLA-4 antibodies
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered human anti-CTLA-4 antibodies
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Primers for site-directed mutagenesis
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Primers for site-directed mutagenesis
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Biological activity of the anti-murine CD4 antibody GK1.5 harboring a human IgG1 Fc
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Biological activity of the anti-murine CD4 antibody GK1.5 harboring a human IgG1 Fc
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Primers for site-directed mutagenesis
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Primers for site-directed mutagenesis
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered murine anti-CCR8 antibodies
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered murine anti-CCR8 antibodies